论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
基于癌变过程中的分子生物学探究肺腺癌预防和药物开发的理论依据
Authors Zhang H, Guo L, Chen J
Received 5 February 2020
Accepted for publication 14 March 2020
Published 14 April 2020 Volume 2020:13 Pages 3085—3091
DOI https://doi.org/10.2147/OTT.S248436
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Takuya Aoki
Abstract: Lung adenocarcinoma (LUAD) is the most common and aggressive subtype of lung cancer with the greatest heterogeneity and aggression. Inspite of recent years’ achievements in understanding the pathogenesis of this disease, as well as the development of new therapeutic approaches, our knowledge on crucial early molecular events during its development is still rudimentary. Recent classification and grading of LUAD has postulated that LUAD does not arise spontaneously, but through a stepwise process from lung adenomatous premalignancy atypical adenomatous hyperplasia to adenocarcinoma in situ, minimally invasive adenocarcinoma, and eventually frankly invasive predominant adenocarcinoma. In this review, we discuss the molecular processes that drive the evolutionary process that results in the formation of LUAD. We also describe how to handle lung premalignancy in clinical settings based on the most recent advances in genomic biology and our own understanding of lung cancer prevention.
Keywords: lung adenocarcinoma, molecular biology, pathogenesis, cancer prevention